Figure 1From: Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-upTumor shrinkage assessed by computed tomography. (a and b) Mediastinal and chest progression without treatment in March 2009; (c and d) tumor shrinkage of 90% according to RECIST criteria in January 2011 after 10 months of Sorafenib; (e and f) stable disease in January 2013.Back to article page